CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.
17 reports, 5 independent
Updated Wed 00:00
Mostly repetition
Reached 2 outlets in its first 24 hours
- Reports
- 17
- Developments
- 5
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CRISPR Therapeutics relies on Vertex Pharmaceuticals for Casgevy commercialization.1 source
Vertex received FDA approval for expanded use of genetic therapy CASGEVY.1 source
CRISPR Therapeutics and Vertex Pharmaceuticals collaborated on the medicine Casgevy.1 source
Successful development of Casgevy in collaboration with Vertex.1 source
Successful commercialization of Casgevy driven by Vertex, providing revenue for CRISPR Therapeutics.1 source
Keep exploring
The entities involved
-
CRISPR Therapeutics
company in Basel, Switzerland
Nothing else this week.
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- fool.com
- finanznachrichten.de
- fool.com
- Motley FoolHere's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be
- ZacksCan Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States and Eu
- Motley FoolUp 50% in 3 Months, Is This Stock Still a Buy? CRISPR Therapeutics' shares have rebounded sharply in recent months. The company has made decent progress with a promising pipeline candidate. While som
- ZacksCRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption CRISPR Therapeutics CRSP reported a second-quarter 2025 loss of $2.40 per share, which was wider than the year-ago period’s loss
- ZacksCRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline u
- Motley Fool3 Monster Stocks in the Making to Buy Right Now CRISPR Therapeutics is still in its early growth stage. Summit Therapeutics has plenty of upside potential remaining. Viking Therapeutics is targeting
- Unknown outlet
- Unknown outlet
- Unknown outlet
- Unknown outlet